PC
DNTH icon

PA Capital’s Dianthus Therapeutics DNTH Stock Holding History

PA Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$109K Buy
1,006
+317
+46% +$37.6K 0.08% 167
2020
Q2 		$83K Buy
+689
New +$97.1K 0.06% 161

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PA Capital's DNTH Position: Q3 2020 in Review

PA Capital increased its Dianthus Therapeutics (DNTH) stake by 46% in Q3 2020, buying an estimated $37.6K and bringing the position to 1,006 shares worth $109K. The position accounts for 0.08% of the portfolio, ranked #167.

PA Capital first reported a position in DNTH in Q2 2020 and has held it in 2 quarters since. 94 funds tracked by Wall St. Rank hold DNTH as of Q3 2020.

  • PA Capital held 1,006 shares of Dianthus Therapeutics worth $109K as of Q3 2020.
  • PA Capital bought 317 Dianthus Therapeutics shares in Q3 2020, an estimated $37.6K.
  • Dianthus Therapeutics made up 0.08% of PA Capital's portfolio in Q3 2020, its #167 holding.
  • PA Capital first reported a position in Dianthus Therapeutics in Q2 2020 and has held it in 2 quarters since.
  • 94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.